Insulin resistance and metabolic diseases - a review
DOI:
https://doi.org/10.12775/JEHS.2024.61.012Keywords
insuline resistance, obesity, diabetes, NAFLD, CVDAbstract
Introduction: This review paper aims to discuss the effects of insulin resistance, and its association with various metabolic diseases. Insulin resistance (IR), characterized by diminished tissue responsiveness to physiological insulin levels, is a key component in various metabolic diseases, including type 2 diabetes, cardiovascular disorders (CVDs), obesity, and non-alcoholic fatty liver disease (NAFLD).
State of knowledge The consequences of IR are profound; in type 2 diabetes, it hinders glucose utilization by muscle cells, leading to hyperglycemia, muscle damage, and loss of mass and strength. IR also plays a central role in NAFLD, promoting lipid accumulation, hepatic inflammation, fibrosis, and cell death.
Materials and methods: A review of chosen literature in the PubMed and Google Scholar databases was conducted, using the following key words: „Insulin resistane”, „Insulin resistance in obesity”, „Obesity”, „Insulin resistance NAFLD”, „Diebetes”, „Insulin resistance CVD”
Summary: The consequences of insulin resistance are far-reaching. In the context of type 2 diabetes, it impedes glucose utilization by muscle cells, resulting in hyperglycemia and subsequent muscle cell damage, contributing to loss of mass and strength. Insulin resistance is also a central player in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), fostering lipid accumulation, hepatic inflammation, and, ultimately, fibrosis and cell death.
Conclusions: In conclusion, understanding insulin resistance is paramount in addressing the rising prevalence of metabolic diseases globally Controlling insulin resistance emerges as a crucial aspect of managing these metabolic disorders and their complications. Further research into the mechanisms of IR formation and effective intervention strategies is imperative for improving public health outcomes.
References
Lewis GF, Brubaker PL. The discovery of insulin revisited: lessons for the modern era. J Clin Invest. 2021;131(1). doi:10.1172/JCI142239
Vecchio I, Tornali C, Bragazzi NL, Martini M. The Discovery of Insulin: An Important Milestone in the History of Medicine. Front Endocrinol (Lausanne). 2018;9:613. doi:10.3389/FENDO.2018.00613
Rahman MS, Hossain KS, Das S, et al. Role of insulin in health and disease: An update. Int J Mol Sci. 2021;22(12). doi:10.3390/ijms22126403
Wendt A, Eliasson L. Pancreatic α-cells - The unsung heroes in islet function. Semin Cell Dev Biol. 2020;103:41-50. doi:10.1016/J.SEMCDB.2020.01.006
Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A. 2006;103(7):2334. doi:10.1073/PNAS.0510790103
Fu Z, Gilbert ER, Liu D. Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes. Curr Diabetes Rev. 2013;9(1):25. doi:10.2174/15733998130104
Park SY, Gautier JF, Chon S. Assessment of Insulin Secretion and Insulin Resistance in Human. Published online 2021. doi:10.4093/dmj.2021.0220
Lee SH, Park SY, Soo Choi C. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Published online 2022. doi:10.4093/dmj.2021.0280
Medycyna po Dyplomie - Jak prawidłowo rozpoznać insulinooporność – czy i jak lec... Accessed January 13, 2024. https://podyplomie.pl/medycyna/26808,jak-prawidlowo-rozpoznac-insulinoopornosc-czy-i-jak-leczyc
Færch K, Vistisen D, Pacini G, et al. Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. Diabetes. 2016;65(11):3473-3481. doi:10.2337/DB16-0240
Davidovici BB, Sattar N, Jörg PC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-1796. doi:10.1038/JID.2010.103
Csajbók ÉA, Tamás G. Cerebral cortex: a target and source of insulin? Diabetologia. 2016;59(8):1609-1615. doi:10.1007/S00125-016-3996-2
Cherrington AD, Edgerton D, Sindelar DK. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia. 1998;41(9):987-996. doi:10.1007/S001250051021
Ghadieh HE, Gastaldelli A, Najjar SM. Role of Insulin Clearance in Insulin Action and Metabolic Diseases. Int J Mol Sci. 2023;24(8). doi:10.3390/IJMS24087156
Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98:2133-2223. doi:10.1152/physrev
Kolb H, Kempf K, Röhling M, Martin S. Insulin: too much of a good thing is bad. BMC Med. 2020;18(1). doi:10.1186/S12916-020-01688-6
da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiol Rep. 2020;8(19). doi:10.14814/phy2.14607
Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785-789. doi:10.1038/378785A0
Maruši M, Pai M, Knobloch M, Liberati Pršo AM. Review Article NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Published online 2021. doi:10.1155/2021/6613827
Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33(2):283-303. doi:10.1016/j.ecl.2004.03.002
Bermudez V, Salazar J, Martínez MS, et al. Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela. Adv Prev Med. 2016;2016:1-13. doi:10.1155/2016/9405105
Himsworth HP. Diabetes mellitus: Its differentiation into insulin-sensitive and insulin-insensitive types*. Diabetic Medicine. 2011;28(12):1440-1444. doi:10.1111/J.1464-5491.2011.3508.X
da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiol Rep. 2020;8(19). doi:10.14814/PHY2.14607
World Health Organization. WHO European Regional Obesity Report 2022. Published online 2022:1-220. Accessed January 21, 2024. https://www.who.int/europe/publications/i/item/9789289057738
Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. doi:10.1016/J.METABOL.2022.155217
Simmonds M, Burch J, Llewellyn A, et al. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess (Rockv). 2015;19(43):1-336. doi:10.3310/hta19430
Obesity and overweight. Accessed January 14, 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial basis and therapeutic strategies in metabolism-related diseases. Nutrients. 2021;13(8). doi:10.3390/nu13082830
Muir LA, Neeley CK, Meyer KA, et al. Adipose tissue fibrosis, hypertrophy, and hyperplasia: correlations with diabetes in human obesity. Obesity (Silver Spring). 2016;24(3):597. doi:10.1002/OBY.21377
Bays HE, González-Campoy JM, Henry RR, et al. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract. 2008;62(10):1474. doi:10.1111/J.1742-1241.2008.01848.X
Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6(3):343-368. doi:10.1586/14779072.6.3.343
Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U. Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity. Physiol Rev. 2018;98(4):1911-1941. doi:10.1152/PHYSREV.00034.2017
Fabbrini E, Sullivan S, Klein S. Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic and Clinical Implications. Hepatology. 2010;51(2):679. doi:10.1002/HEP.23280
Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes Res. 1996;4(2):201-203. doi:10.1002/J.1550-8528.1996.TB00535.X
Di Bonito P, Pacifico L, Licenziati MR, et al. Elevated blood pressure, cardiometabolic risk and target organ damage in youth with overweight and obesity. Nutr Metab Cardiovasc Dis. 2020;30(10):1840-1847. doi:10.1016/J.NUMECD.2020.05.024
Diabetes. Accessed January 20, 2024. https://www.who.int/health-topics/diabetes?gclid=Cj0KCQiA-62tBhDSARIsAO7twbaGlU_tfVyinxa6qIknHLsi2Yh5Qg_qg7400RxKKhXkvB_Ov_Veh4AaAjGUEALw_wcB#tab=tab_1
Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients. 2021;13(8). doi:10.3390/NU13082830
Zhou B, Lu Y, Hajifathalian K, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet. 2016;387(10027):1513. doi:10.1016/S0140-6736(16)00618-8
Hyperglycemia Predicts Persistently Lower Muscle Strength With Aging. Published online 2015. doi:10.2337/dc14-1166
Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res. 2013;43(1):51. doi:10.1111/J.1872-034X.2012.01031.X
Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring HU. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12(12):721-737. doi:10.1038/NRNEPH.2016.145
Sȩdzikowska A, Szablewski L. Insulin and Insulin Resistance in Alzheimer’s Disease. Int J Mol Sci. 2021;22(18). doi:10.3390/IJMS22189987
Burden of disease from diabetes - PAHO/WHO | Pan American Health Organization. Accessed January 20, 2024. https://www.paho.org/en/enlace/burden-disease-diabetes
English | World Gastroenterology Organisation. Accessed January 20, 2024. https://www.worldgastroenterology.org/guidelines/nafld-nash/nafld-nash-english
Hoyumpa AM, Greene HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis. 1975;20(12):1142-1170. doi:10.1007/BF01070758
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-1609. doi:10.1053/J.GASTRO.2012.04.001
Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, Muscle and Adipose Tissue Insulin Action is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects. Gastroenterology. 2008;134(5):1369. doi:10.1053/J.GASTRO.2008.01.07
Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87(7):3023-3028. doi:10.1210/JCEM.87.7.8638
Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32 Suppl 3(SUPPL. 3):14-23. doi:10.1046/J.1365-2362.32.S3.3.X
Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72-81. doi:10.1016/j.molmed.2007.12.003
World-Heart-Report-2023.
Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):E139-E596. doi:10.1161/CIR.0000000000000757
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122. doi:10.1186/S12933-018-0762-4
Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007;298(17):2028-2037. doi:10.1001/JAMA.298.17.2028
Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci U S A. 2000;97(4):1784. doi:10.1073/PNAS.97.4.1784
Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A. Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders. Mediators Inflamm. 2016;2016. doi:10.1155/2016/3634948
Pascual F, Coleman RA. Fuel Availability and Fate in Cardiac Metabolism: A Tale of Two Substrates. Biochim Biophys Acta. 2016;1860(10):1425. doi:10.1016/J.BBALIP.2016.03.014
O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1-12. doi:10.1111/OBR.12229
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marta Drabczyk, Kamila Kosyra, Inga Magda, Zuzanna Marczyńska, Antoni Zyśk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 280
Number of citations: 0
